title: Effect of MicroRNA-30e on the Behavior of Vascular Smooth Muscle Cells via Targeting Ubiquitin-Conjugating Enzyme E2I.
abstract: Many microRNAs (miRNAs) have recently been shown to demonstrate critical roles in differentiation, proliferation and migration of vascular smooth muscle cells (VSMCs).
  
  
  
  In this study, a certain amount of miRNA expression in VSMCs was evaluated by real-time polymerase chain reaction, and it was found that microRNA-30e (miR-30e) was expressed more strongly than other common vascular well-expressed miRNAs in vitro. Subsequently, both a gain and loss of function study was performed in vitro and in vivo. It was found that miR-30e in VSMCs was strongly downregulated concomitantly with stimulation, and miR-30e inhibited VSMCs proliferation and migration both in vitro and in vivo. Furthermore, ubiquitin-conjugating enzyme E2I (Ube2i) was identified as the target gene of endogenous miR-30e by luciferase reporter assay, and it was confirmed that overexpression of miR-30e significantly reduced Ube2i and inhibited the phenotypic switch of VSMCs. Knockdown of Ube2i had an influence over the proliferation and migration of cultured VSMCs, as same as the miR-30e mimic did. Overexpression of miR-30e induced the apoptosis of VSMCs and deregulated the protein expression of IkBα, which is crucial for the NFκB signal pathway.
  
  
  
  The results of this study indicated that miR-30e in VSMCs exerted an anti-atherosclerosis effect via inhibiting proliferation and migration, and promoting apoptosis of VSMCs. More specifically, it was demonstrated that miR-30e exhibited these effects on VSMCs partially through targeting Ube2i and downregulating the IκBα/NFκB signaling pathway.
authors.affiliation: Institute of Cardiovascular Disease, Xuzhou Medical University.
authors.forename: Yu
authors.initials: Y
authors.lastname: Zong
authors.forename: Pei
authors.initials: P
authors.lastname: Wu
authors.forename: Changsheng
authors.initials: C
authors.lastname: Nai
authors.forename: Yuanyuan
authors.initials: Y
authors.lastname: Luo
authors.forename: Fengwang
authors.initials: F
authors.lastname: Hu
authors.forename: Wen
authors.initials: W
authors.lastname: Gao
authors.forename: Nana
authors.initials: N
authors.lastname: Zhai
authors.forename: Tongda
authors.initials: T
authors.lastname: Xu
authors.forename: Dongye
authors.initials: D
authors.lastname: Li
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D017209:Apoptosis / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000494:pharmacology*; D009131:Muscle, Smooth, Vascular / Q000166:cytology*; D032389:Myocytes, Smooth Muscle / Q000187:drug effects*; D000072000:NF-KappaB Inhibitor alpha / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D044763:Ubiquitin-Conjugating Enzymes / Q000187:drug effects* / Q000235:genetics; D000098843:Ubiquitin-Conjugating Enzyme UBC9
chemical_list: C546086:MIRN30b microRNA, human; D035683:MicroRNAs; D016328:NF-kappa B; D000072000:NF-KappaB Inhibitor alpha; D044763:Ubiquitin-Conjugating Enzymes; D000098843:Ubiquitin-Conjugating Enzyme UBC9